ATE553761T1 - Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafür - Google Patents
Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafürInfo
- Publication number
- ATE553761T1 ATE553761T1 AT05854594T AT05854594T ATE553761T1 AT E553761 T1 ATE553761 T1 AT E553761T1 AT 05854594 T AT05854594 T AT 05854594T AT 05854594 T AT05854594 T AT 05854594T AT E553761 T1 ATE553761 T1 AT E553761T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- citrate salt
- crystalline
- discussed
- application
- Prior art date
Links
- 229940122444 Chemokine receptor antagonist Drugs 0.000 title 1
- 239000002559 chemokine receptor antagonist Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 150000001860 citric acid derivatives Chemical class 0.000 abstract 4
- 230000004913 activation Effects 0.000 abstract 2
- 230000007115 recruitment Effects 0.000 abstract 2
- ZGFJFBOLVLFLLN-YTTGMZPUSA-N (4s)-4-(4-chlorophenyl)-1-[3-[9-(2-hydroxypropan-2-yl)-5h-[1]benzoxepino[3,4-b]pyridin-11-ylidene]propyl]-3,3-dimethylpiperidin-4-ol Chemical compound C1([C@]2(CCN(CC2(C)C)CCC=C2C3=CC=CN=C3COC3=CC=C(C=C32)C(C)(O)C)O)=CC=C(Cl)C=C1 ZGFJFBOLVLFLLN-YTTGMZPUSA-N 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63721304P | 2004-12-17 | 2004-12-17 | |
| PCT/US2005/045915 WO2006066200A2 (en) | 2004-12-17 | 2005-12-19 | Solid forms of a chemokine receptor antagonist and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE553761T1 true ATE553761T1 (de) | 2012-05-15 |
Family
ID=36588631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05854594T ATE553761T1 (de) | 2004-12-17 | 2005-12-19 | Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafür |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7960549B2 (OSRAM) |
| EP (1) | EP1841429B1 (OSRAM) |
| JP (3) | JP5308030B2 (OSRAM) |
| CN (1) | CN101119725B (OSRAM) |
| AT (1) | ATE553761T1 (OSRAM) |
| AU (1) | AU2005316340B2 (OSRAM) |
| CA (1) | CA2590157C (OSRAM) |
| ES (1) | ES2386029T3 (OSRAM) |
| WO (1) | WO2006066200A2 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020390992A1 (en) * | 2019-11-29 | 2022-06-09 | Sunshine Lake Pharma Co., Ltd. | Crystalline form of nitrogen-containing tricyclic compound and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613905B1 (en) | 1998-01-21 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US6509346B2 (en) | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| CA2318088A1 (en) | 1998-01-21 | 1999-07-29 | Yoshisuke Nakasato | Chemokine receptor antagonists and methods of use therefor |
| CN1289336A (zh) | 1998-01-21 | 2001-03-28 | 千禧药品公司 | 趋化因子受体拮抗剂和其使用方法 |
| AU2331199A (en) | 1998-09-04 | 2000-03-27 | Kyowa Hakko Kogyo Co. Ltd. | Chemokine receptor antagonists and methods of use therefor |
| US7271176B2 (en) | 1998-09-04 | 2007-09-18 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
| US6503926B2 (en) | 1998-09-04 | 2003-01-07 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| MXPA04004826A (es) | 1998-09-04 | 2004-08-11 | Millenium Pharmaceuticals Inc | Antagonista del receptor de quimioquinas y metodos para su uso. |
| US20020169155A1 (en) | 1998-09-04 | 2002-11-14 | Millennium Pharmaceuticals, Inc. | Chemokine receptor anagonists and methods of use therefor |
| US6288083B1 (en) | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| AU6503900A (en) | 1999-07-28 | 2001-02-19 | Kyowa Hakko Kogyo Co. Ltd. | Chemokine receptor antagonists and methods of use therefor |
| US7541365B2 (en) | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| TWI291467B (en) * | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
-
2005
- 2005-12-19 EP EP05854594A patent/EP1841429B1/en not_active Expired - Lifetime
- 2005-12-19 CA CA2590157A patent/CA2590157C/en not_active Expired - Fee Related
- 2005-12-19 CN CN2005800481176A patent/CN101119725B/zh not_active Expired - Fee Related
- 2005-12-19 AU AU2005316340A patent/AU2005316340B2/en not_active Ceased
- 2005-12-19 US US11/311,574 patent/US7960549B2/en not_active Expired - Fee Related
- 2005-12-19 ES ES05854594T patent/ES2386029T3/es not_active Expired - Lifetime
- 2005-12-19 JP JP2007547000A patent/JP5308030B2/ja not_active Expired - Fee Related
- 2005-12-19 WO PCT/US2005/045915 patent/WO2006066200A2/en not_active Ceased
- 2005-12-19 AT AT05854594T patent/ATE553761T1/de active
-
2011
- 2011-05-26 US US13/116,130 patent/US8481737B2/en not_active Expired - Fee Related
-
2012
- 2012-08-02 JP JP2012172003A patent/JP2012211197A/ja not_active Withdrawn
-
2014
- 2014-12-22 JP JP2014258340A patent/JP2015057445A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101119725A (zh) | 2008-02-06 |
| WO2006066200A2 (en) | 2006-06-22 |
| JP2015057445A (ja) | 2015-03-26 |
| JP2012211197A (ja) | 2012-11-01 |
| CN101119725B (zh) | 2013-04-17 |
| AU2005316340A1 (en) | 2006-06-22 |
| US8481737B2 (en) | 2013-07-09 |
| AU2005316340B2 (en) | 2012-01-19 |
| US7960549B2 (en) | 2011-06-14 |
| ES2386029T3 (es) | 2012-08-07 |
| CA2590157A1 (en) | 2006-06-22 |
| US20070010545A1 (en) | 2007-01-11 |
| EP1841429B1 (en) | 2012-04-18 |
| JP2008524253A (ja) | 2008-07-10 |
| CA2590157C (en) | 2013-11-05 |
| WO2006066200A3 (en) | 2007-01-25 |
| EP1841429A2 (en) | 2007-10-10 |
| JP5308030B2 (ja) | 2013-10-09 |
| HK1109350A1 (en) | 2008-06-06 |
| US20120065223A1 (en) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007058602A3 (en) | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia. | |
| MY153198A (en) | Inhibitors of protein aggregation | |
| NZ617196A (en) | Activin-actrii antagonists and uses for increasing red blood cell levels | |
| DE602006018961D1 (de) | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZOL, ZUBEREITUNGSVERFAHREN DAFÜR UND DESSEN VERWENDUNG ZUR ARZNEIMITTELHERSTELLUNG | |
| WO2005016261A3 (en) | Aripiprazole and haloperidol pamoate salts | |
| MX2010013020A (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| TW200635582A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
| UA90048C2 (ru) | Кондиционированная композиция и способ ее получения | |
| IL189499A (en) | Use of 2,4-diaminopyrimidines or 4-aminopyrimidines for the preparation of a medicament for the treatment of a respiratory disease mediated by a p2x3 or p2x2/3 receptor antagonist | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| TW200619220A (en) | New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament | |
| BRPI0407662A (pt) | derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas | |
| IL169484A (en) | Processes for altering the external appearance of a crystal or reconstituting the monophenyl sodium monophenylate compound, crystals obtained from these processes, pharmaceutical preparations containing them and their use in the treatment of diseases | |
| IL226313A0 (en) | A method for producing gamma-carboxylated human prothrombin, isolated prothrombin produced by such a method, a pharmaceutical preparation including it and its use as drugs and for the production of drugs for the treatment of blood coagulation | |
| MY151075A (en) | Crystalline form of a quinolone-carboxamide compound | |
| WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
| IL165505A0 (en) | 2-heteroaryl carboxamides | |
| EP2543384A3 (en) | Treatment of conditions involving demyelination | |
| PL1680112T3 (pl) | N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę | |
| WO2004082584A3 (en) | 5ht2c receptor antagonists in the treatment of schizophrenia | |
| WO2005089486A3 (en) | Methods for treating alcoholism | |
| EP4566667A3 (en) | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling | |
| MY145581A (en) | Combination of ferroquine and an artemisinin derivative for the treatment of malaria |